Clinical trials: Hospitalized COVID-19
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 To evaluate the clinical efficacy of…
- Trial name
- NCT04426695
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 123 sites in United States, Brazil and 4 more
- Volunteers
- 2,252 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19
The purpose of this study is to assess the efficacy and safety of the administration of anti-SARS-CoV-2 convalescent plasma in COVID-19 patients who are sick enough to warrant hospitalization, but not yet admitted to the ICU…
- Trial name
- NCT04467151
- Testing
- anti-SARS-CoV-2 plasma
- Sponsor
- Kashif Khan
COVID
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19.
- Trial name
- NCT04382924
- Testing
- NP-120 (Ifenprodil)
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 168 people
- Sponsor
- Algernon Pharmaceuticals
COVID-19
Study to Assess the Effect of Meplazumab on COVID-19
This phase2/3 study will be conducted to evaluate the safety and efficacy of Meplazumab in addition to Standard of Care for the treatment of Corona Virus Disease(COVID) 19 in hospitalized adults
- Trial name
- NCT04586153
- Testing
- Meplazumab for Injection, Sterile normal saline (0.9%)
- Where
- Brazil
- Volunteers
- 174 people
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
SARS-CoV 2, Hospitalisation-Associated Infection
Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients
The inflammation is central in COVID-19 infections. Our aim is to evaluate the clinical value of measuring inflammation by using serum protein electrophoresis (SPE).
- Trial name
- COVELEC (NCT04414059)
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Elsan
COVID-19 Pandemic, Children, Only
Quality of Nursing Care During The Covid-19 Pandemic
Enabling school-age children to evaluate the care they receive provides feedback on the quality of care by determining children's satisfaction with care, and gives important feedback on the quantity and quality of care.
- Conditions
- COVID-19 Pandemic, Children, Only, Hospitalism, Nurse's Role
- Trial name
- NCT05841602
- Testing
- descriptive
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Tokat Gaziosmanpasa University
Covid-19, Sars-CoV2
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
This is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus…
- Conditions
- Covid-19, Sars-CoV2, Diabete Mellitus, Cardiopathy
- Trial name
- NCT04407182
- Testing
- Viusid and Asbrip
- Where
- Ecuador
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Covid19, Corona Virus Infection
A Study of Baricitinib (LY3009104) in Children With COVID-19
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
- Trial name
- COV-BARRIER (NCT05074420)
- Testing
- Baricitinib
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Covid19, C-reactive Protein
Early Predictors of Prognostic Course in Patients With COVID-19 in Critical or Semi-intensive Area.
Although the recent literature is building a remarkable background to answer the many unknowns related to SARS-CoV-2 infection, it is absolutely necessary to finalize every clinical effort to collect data that may be useful, in a…
- Conditions
- Covid19, C-reactive Protein, Procalcitonin, D-dimer
- Trial name
- NCT04873388
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Turin, Italy
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Immunophenotyping Assessment in a COVID-19 Cohort
This surveillance study will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions in order to identify…
- Trial name
- IMPACC (NCT04378777)
- Testing
- Biological sample collection, Data Collection: Clinical Care Assessments
- Where
- 17 sites in United States
- Volunteers
- 1,227 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Lung Injury
Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19
COVID-19 is impacting on health systems in Brazil and worldwide. Reducing the risk of clinical deterioration and prolonged disease duration in hospitalized patients with COVID-19 may alleviate the burden caused by the pandemic.
- Trial name
- NCT04470297
- Testing
- Ramelteon 8mg
- Volunteers
- 100 people
- Sponsor
- Associação Fundo de Incentivo à Pesquisa
Covid19
Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease,COVID-19, in Hospitalized Patients
Patients hospitalized for COVID-19 may need intensive care (e.g. mechanical ventilation) during hospitalization. Some risk factors are already known but better targeting of such patients is still needed, at least because existing…
- Trial name
- MicrobioCOVID (NCT04669938)
- Testing
- oropharyngeal and intestinal microbiota, host genotype, host immune factors
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19 SARS-CoV-2 Infection
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT06679140
- Testing
- ibuzatrelvir
- Where
- 256 sites in United States, Argentina and 17 more
- Volunteers
- 2,330 people
- Sponsor
- Pfizer
COVID-19
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of LY3819253 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780268
- Testing
- LY3819253, Remdesivir
- Where
- 57 sites in United States, Denmark and 2 more
- Volunteers
- 314 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III trial, and will be conducted globally.
- Trial name
- NCT04644185
- Testing
- SCTA01
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 102 people
- Sponsor
- Sinocelltech Ltd.
SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome
Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
Background:The impact of the emergence of SARS-CoV-2 variants on the severity and clinical outcomes of COVID-19 is controversial.
- Conditions
- SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Mutation
- Trial name
- SEVARVIR (NCT05162508)
- Testing
- Nasopharyngeal swab
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID -19, Acute Kidney Injury
Acute Kidney Injury in Critical COVID-19: Outcomes and Risks
This retrospective observational study aims to determine the incidence of acute kidney injury (AKI) associated with COVID-19, risk factors, and effects on mortality for intensive care unit patients.
- Conditions
- COVID -19, Acute Kidney Injury, Intensive Care Unit (ICU) Admission, Mortality
- Trial name
- NCT07089693
- Where
- Turkey (Türkiye)
- Volunteers
- 238 people
- Sponsor
- Ankara University
Solid Tumor, Sars-CoV2
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of…
- Conditions
- Solid Tumor, Sars-CoV2, Hematological Malignancy
- Trial name
- NCT04347226
- Testing
- BMS-986253
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Columbia University
Coronavirus Infection
Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study
In the context of COVID-19 pandemic, identifying low-risk patients who can be safely treated at home and high-risk patients requiring hospitalization or even intensive care is crucial for Emergency Departments.
- Trial name
- NCT04657471
- Testing
- revised HOME-CoV score
- Where
- France
- Volunteers
- 1,300 people
- Sponsor
- University Hospital, Angers
COVID-19
CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany
This is a multicenter, observational, prospective, epidemiological cohort study at 45 hospitals in Germany, all part of a German hospital network. All hospitalized patients tested positive for SARS-CoV-2 will be included.
- Trial name
- CORONA Germany (NCT04659187)
- Where
- 8 sites in Germany
- Volunteers
- 4,000 people
- Sponsor
- Asklepios proresearch